Tags

Type your tag names separated by a space and hit enter

Thoracoscopic lobectomy with systemic lymph node dissection for lymph node positive non-small cell lung cancer--is thoracoscopic lymph node dissection feasible?
Thorac Cardiovasc Surg. 2008 Apr; 56(3):162-6.TC

Abstract

INTRODUCTION

The impact of thoracoscopic systemic lymph node dissection (LND) on loco-regional control of non-small cell lung cancer (NSCLC) with positive lymph node metastasis was investigated.

PATIENTS AND METHODS

Thoracoscopic lobectomy with systemic LND was performed for clinical stage I NSCLC. 340 patients were admitted for either a thoracoscopic (n = 98) or a standard open (n = 242) lobectomy with systemic LND. Of those 340 cases, 75 cases (20 thoracoscopic and 55 open) were pathologically diagnosed with node-positive disease. A retrospective chart review of these 75 cases was performed.

RESULTS

No significant difference in the overall or loco-regional recurrence-free survival was observed between the groups. The results of a multivariate analysis of the overall and the loco-regional recurrence-free survival demonstrated that the significant factors were tumor size for overall recurrence-free survival, and sex and surgical procedure (use of thoracoscopic surgery) for loco-regional recurrence-free survival, respectively.

CONCLUSION

In general, thoracoscopic lobectomy for c-stage I disease may have no survival disadvantage over open procedures. It might, however, increase the risk of local recurrence when used to treat pathologically node-positive disease. Caution should be used when treating those cases with thoracoscopic surgery.

Authors+Show Affiliations

Department of Surgery II, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka City, Fukuoka, Japan. tshiraishi-ths@umin,ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18365976

Citation

Shiraishi, T, et al. "Thoracoscopic Lobectomy With Systemic Lymph Node Dissection for Lymph Node Positive Non-small Cell Lung Cancer--is Thoracoscopic Lymph Node Dissection Feasible?" The Thoracic and Cardiovascular Surgeon, vol. 56, no. 3, 2008, pp. 162-6.
Shiraishi T, Hiratsuka M, Yoshinaga Y, et al. Thoracoscopic lobectomy with systemic lymph node dissection for lymph node positive non-small cell lung cancer--is thoracoscopic lymph node dissection feasible? Thorac Cardiovasc Surg. 2008;56(3):162-6.
Shiraishi, T., Hiratsuka, M., Yoshinaga, Y., Yamamoto, S., Iwasaki, A., & Shirakusa, T. (2008). Thoracoscopic lobectomy with systemic lymph node dissection for lymph node positive non-small cell lung cancer--is thoracoscopic lymph node dissection feasible? The Thoracic and Cardiovascular Surgeon, 56(3), 162-6. https://doi.org/10.1055/s-2007-989368
Shiraishi T, et al. Thoracoscopic Lobectomy With Systemic Lymph Node Dissection for Lymph Node Positive Non-small Cell Lung Cancer--is Thoracoscopic Lymph Node Dissection Feasible. Thorac Cardiovasc Surg. 2008;56(3):162-6. PubMed PMID: 18365976.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Thoracoscopic lobectomy with systemic lymph node dissection for lymph node positive non-small cell lung cancer--is thoracoscopic lymph node dissection feasible? AU - Shiraishi,T, AU - Hiratsuka,M, AU - Yoshinaga,Y, AU - Yamamoto,S, AU - Iwasaki,A, AU - Shirakusa,T, PY - 2008/3/28/pubmed PY - 2008/8/30/medline PY - 2008/3/28/entrez SP - 162 EP - 6 JF - The Thoracic and cardiovascular surgeon JO - Thorac Cardiovasc Surg VL - 56 IS - 3 N2 - INTRODUCTION: The impact of thoracoscopic systemic lymph node dissection (LND) on loco-regional control of non-small cell lung cancer (NSCLC) with positive lymph node metastasis was investigated. PATIENTS AND METHODS: Thoracoscopic lobectomy with systemic LND was performed for clinical stage I NSCLC. 340 patients were admitted for either a thoracoscopic (n = 98) or a standard open (n = 242) lobectomy with systemic LND. Of those 340 cases, 75 cases (20 thoracoscopic and 55 open) were pathologically diagnosed with node-positive disease. A retrospective chart review of these 75 cases was performed. RESULTS: No significant difference in the overall or loco-regional recurrence-free survival was observed between the groups. The results of a multivariate analysis of the overall and the loco-regional recurrence-free survival demonstrated that the significant factors were tumor size for overall recurrence-free survival, and sex and surgical procedure (use of thoracoscopic surgery) for loco-regional recurrence-free survival, respectively. CONCLUSION: In general, thoracoscopic lobectomy for c-stage I disease may have no survival disadvantage over open procedures. It might, however, increase the risk of local recurrence when used to treat pathologically node-positive disease. Caution should be used when treating those cases with thoracoscopic surgery. SN - 0171-6425 UR - https://www.unboundmedicine.com/medline/citation/18365976/Thoracoscopic_lobectomy_with_systemic_lymph_node_dissection_for_lymph_node_positive_non_small_cell_lung_cancer__is_thoracoscopic_lymph_node_dissection_feasible L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-989368 DB - PRIME DP - Unbound Medicine ER -